Cytokines within endometrium participate in both menstruation and implantat
ion but also contribute to the defence mechanisms of the mucosal epithelium
. Endometrium is under the control of steroid hormones, particularly proges
terone and, thus, control of cytokines by this steroid is important. Althou
gh appreciable numbers of progesterone receptors are not found in endometri
al leucocytes, progesterone can modulate cytokines by acting on uterine cel
ls expressing the receptor. The NF kappaB pathway is important in the contr
ol of cytokine synthesis and can modulate production of chemokines, matrix
metalloproteinases and the inducible prostaglandin synthesis enzyme COX-2.
NF kappaB activity can be inhibited by progesterone by either stimulating s
ynthesis of I kappaB, the molecule that restrains NF kappaB in the cytosol,
or after binding to the nuclear receptor, competing with NF kappaB for rec
ognition sites on the relevant gene. In this way, progesterone can limit pr
o-inflammatory pathways. The major palliatives for endometrial dysfunctions
such as menorrhagia and dysmenorrhoea have been the non-steroidal anti-inf
lammatory drugs that inhibit prostaglandin synthesis. Prostaglandins have m
ajor effects on cytokine production but the direct action of prostaglandin
E on leucocytes is not a pro-inflammatory response but is to stimulate inte
rleukin 10 and inhibit interleukin 12 synthesis. The likely effect of the n
on-steroidal anti-inflammatory drugs is on the cells surrounding the small
blood vessels, where a synergistic action between prostaglandin and chemoki
ne will induce leucocyte entry and activation leading to lysis of connectiv
e tissue and menstruation. At the time of implantation, tight control of cy
tokine synthesis is required. Although leukaemia inhibitory factor is essen
tial to implantation, the mouse knockout models show that the prostaglandin
system is also essential but that there are mutually supportive pathways t
hat compensate for the knockout of many cytokines.